SEC Tracker
Get the app

Supernus Pharmaceuticals

Georges Gemayel (Director) reported 27,277 SUPN

Form
4
Filed
Importance
Routine
  1. Disposed of 27,277 common shares
  2. Converted 2,989 restricted stock units (shares paid out over time)
  3. Converted multiple director stock options

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Supernus Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  2. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  3. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  4. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.